Power Law company profile

NewAmsterdam Pharma

Biotech & Life Sciences · Aventura, United States · Founded 2019 Thoroughbred

Developing transformative, clinically validated oral therapies for patients with metabolic diseases

Valuation

$2.65B

Market cap · May/2026

Revenue

$23M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

5 investors on NewAmsterdam Pharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

Forbion Capital Partners

Morningside

Ascendant BioCapital

Peter Thiel

Series B+ 1 investor entered at this stage

BioGeneration Ventures

Global footprint

Where NewAmsterdam Pharma has talent and traffic

Workforce by country

4 countries with
team presence

🇺🇸 United States87.2%

🇳🇱 Netherlands8.9%

🇨🇭 Switzerland1.6%

🇬🇧 United Kingdom1.5%

4 countries shown

Web traffic by country

6.5K monthly visits
across markets

🇺🇸 United States73.8%

🇮🇳 India10.8%

🇵🇭 Philippines7.7%

🇧🇪 Belgium3.1%

🇳🇱 Netherlands3.1%

Top 5 markets shown

Market sentiment

What the market is saying about NewAmsterdam Pharma

An AI-synthesized read of the highest-engagement posts about NewAmsterdam Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NewAmsterdam Pharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles